SCHEMBL8001609

SCHEMBL8001609

CC1(C)C(=O)N(c2ccccc2Cl)C(=O)N1Cc1ccccc1Oc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
NR1H2 P55055 1/20 0.40
TAS2R8 Q9NYW2 2/20 0.40
TNF P01375 1/20 0.39
FAAH O00519 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK8 P45983 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SLC6A4 P31645 3/20 0.39
HTR2A P28223 2/20 0.39
KCNH2 Q12809 2/20 0.37
CYP19A1 P11511 1/20 0.37
PGR P06401 1/20 0.37
CCR8 P51685 1/20 0.37
RIPK1 Q13546 1/20 0.36
SLC6A2 P23975 1/20 0.36
NPBWR1 P48145 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8021527 0.93 HDAC1 (0.43) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL12873244 0.91 HDAC1 (0.48) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL8023332 0.89 SLC6A4 (0.41) HDAC1HDAC6NR1H2TAS2R8FAAH
SCHEMBL8023329 0.89 SLC6A4 (0.41) HDAC1HDAC6TAS2R8FAAHSLC6A4
SCHEMBL12873215 0.88 HDAC1 (0.44) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL12873223 0.88 HDAC1 (0.56) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL8010597 0.87 HDAC1 (0.43) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL8010587 0.87 HDAC1 (0.43) HDAC1HDAC6TAS2R8TNFFAAH
SCHEMBL8016194 0.86 SLC6A4 (0.42) HDAC1HDAC6NR1H2TAS2R8TNF
SCHEMBL8015549 0.86 HDAC1 (0.45) HDAC1HDAC6NR1H2TAS2R8TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed
WO-2009097998-A1 ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046185-A1 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof PGC, LIPC, CEL HDAC1 1393/4885HDAC6 2952/4885NR1H2 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.